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Patients with acute myeloid leukemia (AML) in relapse or refractory to induction therapy have a
dismal prognosis. Allogeneic hematopoietic stem cell transplantation is the only curative option. In
these patients, we aimed to compare the results of a myeloablative transplant versus a sequential
approach consisting in a cytoreductive chemotherapy followed by a reduced intensity conditioning
regimen and prophylactic donor lymphocytes infusions. We retrospectively analyzed 99 patients
aged 18-50 years, transplanted for a refractory (52%) or a relapsed AML not in remission (48%).
Fifty-eight patients received a sequential approach and 41 patients a myeloablative conditioning
regimen. Only 6 patients received prophylactic donor lymphocytes infusions. With a median
follow-up of 48 months, 2-year overall survival was 39%, 95% confidence interval (CI) (24-53) in
the myeloablative group versus 33%, 95% CI (21-45) in the sequential groups (P5 .39), and 2-year
cumulative incidence of relapse (CIR) was 57% versus 50% respectively (P5 .99). Nonrelapse
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mortality was not higher in the myeloablative group (17% versus 15%, P5 .44). In multivariate
analysis, overall survival, CIR and nonrelapse mortality remained similar between the two groups.
However, in multivariate analysis, sequential conditioning led to fewer acute grade II-IV graft ver-
sus host disease (GVHD) (HR for sequential approach50.37; 95% CI: 0.21-0.65; P< .001) without
a significant impact on chronic GVHD (all grades and extensive). In young patients with refractory
or relapsed AML, myeloablative transplant and sequential approach offer similar outcomes except
for a lower incidence of acute GvHD after a sequential transplant.
1 | INTRODUCTION
Refractory or relapsed acute myeloid leukemia (AML) is associated with
a dismal prognosis. Approximately, one third of patients younger than
60 years with newly diagnosed AML fail to achieve complete remission
(CR) after induction therapy.1,2 For these resistant patients, chemother-
apy alone does not offer any chance of cure.3 Moreover, among com-
plete responders to induction therapy, half of patients experiences
relapse.1,2 The probability to obtain a second remission with salvage
chemotherapy is lower and patient prognosis is poor2 with a 5-year
overall survival (OS) rate close to 5% to 20%.4–8
To date, allogeneic hematopoietic stem cell transplantation (HSCT)
is the only potentially curative approach in patients with primary
induction failure (PIF) or patients who relapsed, and failed to achieve a
second remission.5–11 In this setting, conventional myeloablative
conditioning (MAC) transplants are usually associated with nonrelapse
mortality (NRM) greater than 40% in historical series.12–17 More
recently, promising results have been reported in patients with refrac-
tory or relapsed AML, using a sequential (SEQ) treatment approach.
This strategy consists in an initial cytoreductive chemotherapy followed
by a reduced-intensity conditioning regimen transplant (RIC) to limit tox-
icity. Prophylactic donor lymphocyte infusions (DLI) are systematically
planned, in the absence of graft versus host disease (GVHD) to reinforce
the graft versus leukemia (GVL) effect.18 Sequential approaches are asso-
ciated to 30%-45% long-term survival in advanced AML patients.19–23
Conversely, major advances in the supportive care of HSCT, such as fun-
gal and viral infections prevention and treatment, or HLA-typing in unre-
lated transplants, have reduced NRM after MAC transplants.24–27 This
evolution leads to reassess the role of MAC transplants in relapsed or
refractory AML.
In the present study, we retrospectively analyzed data from the
Societe Francophone de Greffe de Moelle et de Therapie Cellulaire
(SFGM-TC) to compare the results of SEQ and MAC approaches in
patients transplanted for relapsed or refractory AML.
2 | PATIENTS AND METHODS
2.1 | Study design
The inclusion criteria were (a) non-ex vivo T-cell depleted HSCT per-
formed from January 2006 to December 2013 in SFGM-TC centers, (b)
patients aged 18–50 years at transplant, (c) relapsed AML with active dis-
ease28 or PIF, defined as (i) 5% bone marrow blasts, or (ii) persistence
of blood blasts at least 28 days after the first or second induction treat-
ment, or lack of hematopoietic recovery at 50 days post induction with-
out bone marrow blasts, (d) previous treatment with at least one cycle of
induction chemotherapy course including anthracycline and cytarabine,
(e) transplant from a HLA matched related or unrelated donor or a HLA
9/10 unrelated donor. Patients included in the prospective “SETRIC”
study (NCT01188174) were excluded.
2.2 | Treatment
MAC consisted of 12 Gy-fractionated total body irradiation (TBI) or
12.8 mg/kg intravenous (IV) busulfan, both associated with cyclophos-
phamide. Sequential conditioning regimen was administered as previ-
ously described,19,20 including: FLAMSA (fludarabine (120 mg/m2 total
dose) plus cytarabine (8 g/m2 total dose) plus amsacrine (400 mg/m2
total dose)) or an association of clofarabine (150 mg/m2 total dose) and
cytarabine (5 g/m2 total dose) followed by a RIC (4 Gy TBI, or 6.4 mg/
kg IV busulfan plus cyclophosphamide 80–120 mg/kg and mostly with
antithymocyte globulin (ATG) (Genzyme, Cambridge MA, USA) 5 mg/
kg). In this retrospective study, the type of conditioning regimen
depended on the physician choice. GVHD prophylaxis consisted of
cyclosporine A with mycophenolate mofetil in the SEQ group and
mostly with methotrexate in the MAC group. Prophylactic DLI were to
be administered systematically in the SEQ group in patients without
GVHD after cessation of immunosuppressive therapy. The study was
accepted by the scientific council of the SFGM-TC. Patients and donors
gave informed consent for data analyses, in accordance with the decla-
ration of Helsinki.
2.3 | Outcomes
The neutrophil recovery was defined as three consecutive days with a
neutrophil count >0.5 3 106/L. Platelet recovery was defined as three
consecutive days with a platelet count above 50 3 109/L at least 7
days after the last platelet transfusion. Acute GVHD (aGVHD) and
chronic GVHD (cGVHD) were defined and staged as previously
reported.29–31
2.4 | Statistics
Patient-, disease- and transplantation related characteristics were com-
pared using the chi-square test for categorical variables, Kendall’s tau
for ordinal variables and the Student t test for continuous variables.
The Kaplan-Meier method was used to calculate the probability of OS
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(from the day of transplant to the day of death) and the probability of
disease free survival (DFS) (relapse or death being considered as
events). Cumulative incidence of relapse (CIR) was defined considering
NRM as a competing event. Cumulative incidence of aGVHD and
cGVHD were estimated considering both death and relapse as compet-
ing risks. Patients were censored at last follow-up. OS and DFS curves
were compared using the log-rank test and CIR, NRM and cumulative
incidence of GVHD using the Fine and Gray test. The univariate analy-
sis had included the following variables: relapse risk according to the
European LeukemiaNet (ELN) classification, number of pretransplant
chemotherapy lines, age at transplant, time between diagnosis and day
of transplant (shorter or longer than 6 months), status at transplant
(refractory or relapse), percentage of blood blasts at transplant, per-
centage of bone marrow blasts at transplant, white blood cell count at
transplant, conditioning regimen type, use of ATG in the conditioning
regimen, hematopoietic stem cell source (bone marrow versus periph-
eral blood), donor type (matched vs mismatched), donor gender, cyto-
megalovirus (CMV) status and CD341 cell dose. The number of
pretransplant chemotherapy lines, the age at transplant, the percentage
of blood blasts at transplant, the percentage of bone marrow blasts at
transplant, the white blood cell count at transplant were analyzed as
continuous variables. Cox regression models were used to perform the
multivariate analyses for censored outcomes and Fine and Gay models
for competing risks. P value .10 in univariate analysis was the crite-
rion for a covariate to be included in multivariate models, followed by
backward selection; type of conditioning regimen was forced into the
models. Type I error rate was fixed at 0.05. Statistical analyses were
realized with STATA 12.0 (Stata Corp) and the 3.2.3 version of R
(https://cran.r-project.org).
3 | RESULTS
3.1 | Patients characteristics
Ninety-nine patients were included, 41 in the MAC and 58 in the SEQ
groups. At transplant, 51 patients were in PIF. Two of these patients
lacked hematopoietic recovery at 50 days post induction and 4
received only one intensive chemotherapy course before the trans-
plant, including one who also received additional hypomethylating
agent therapy courses. Forty-eight patients were in relapse with active
disease. Characteristics are summarized in Table 1. Median age at
transplant was 40 in both groups. There was no difference between
the 2 groups regarding the ELN classification, the number of lines of
chemotherapy prior to HSCT and the status of disease at transplant.
There was a trend for a longer time between diagnosis and day of
transplant in the sequential approach group (7.5 months vs 5 months,
P5 .055). Peripheral, but not bone marrow blast percentages at trans-
plant were higher in the SEQ group (7 vs 1% (P5 .01)).
3.2 | Transplant modalities
MAC regimen consisted of busulfan plus cyclophosphamide in 59% of
patients and in TBI plus cyclophosphamide in 41% of patients.
Cytoreductive chemotherapy of the sequential approach was FLAMSA
in 67% of patients (RIC conditioning regimen comprising TBI in 18
patients and busulfan in 21 patients) and the association of clofarabine
and cytarabine in the remaining 33% (RIC conditioning regimen com-
prising TBI in 1 patient and busulfan in 18 patients). Sequential
approaches included ATG in 84% of patients versus only 10% in the
MAC transplants (P< .001).
Both groups appear to be similar with regards to the stem cell
source, which was mostly peripheral stem cells (71% in the MAC group
and 85% in the SEQ group, P5 .10). Donor type was also distributed
similarly with a predominance of unrelated transplant (59% in the MAC
group and 60% in the SEQ group, P5 .79). HLA mismatched unrelated
transplants (9/10) represented 12% of MAC transplant and 17% of
sequential approaches. Numbers of CD34 transplanted cells were close
in both groups: median 5.86 3 106/kg (range 1.7–21.19) in the MAC
group and 6.35 3 106/kg (range 0.85-10.59) in the SEQ group. Only 5
(8.6%) patients of the SEQ group received prophylactic DLI. Reasons of
nonadministration were early deaths in 16 patients, early relapse in 8
patients, occurrence of GVHD in 11 patients and unknown in 18
patients. Prophylactic DLI were administered in one patient of the
MAC group. Eight (13.7%) patients from the SEQ and 5 (12.1%) from
the MAC groups received DLI after AML relapse.
3.3 | Impact of conditioning regimen on outcomes
Seven patients died before Day 130 from infectious complications
without neutrophil and platelet recovery. The remaining 92 patients
reached a neutrophil count over 0.5 3 106/L with a median time of 17
days (range, 6–33) in the MAC group and 15 days (range, 9–41) in the
SEQ group (P5 .78). Ninety two percent of patients reached a platelet
count above 50 3 106/L in the MAC group with a median of 20 days
(range, 7–379) and 98% in the SEQ group with a median of 16 days
(range, 0–60) (P5 .22).
Cumulative incidence of acute and chronic GVHD were signifi-
cantly higher in the MAC group: aGVHD grade II-IV and III-IV occurred
in 68% of the MAC group vs 36% in the SEQ group (P5 .002) and in
29% of the MAC group vs 14% in the SEQ group respectively
(P5 .056). Cumulative incidences of all grade cGVHD and extensive
cGVHD at 2 years were 44% 95%CI (28–60) in the MAC group vs 24%
95%CI (13.0–35.0) in the SEQ group (P5 .048) and 22% 95%CI (9.0–
36.0) in the MAC group vs and 7% 95%CI (1.0–14.0) in the SEQ group
(P5 .048) respectively. In univariate analysis, use of ATG was strongly
associated with the incidence of GVHD: HR: 0.35, 95%CI (0.22–0.48);
P5 .017 for grade II-IV aGVHD, and HR: 0.23, 95%CI (0.11–0.35);
P5 .043 for cGVHD (Table 2).
There were no differences between the two approaches in terms
of OS, DFS, CIR and NRM (Figure 1). With a median follow-up of 4
years, two year-OS was 39%, 95%CI (24–53) in the MAC group and
33%, 95%CI (21.0–45.0) in the SEQ group (P5 .39). Estimated 2-year
DFS was 29%, 95%CI (16.0–43.0) in the MAC group and 33%, 95%CI
(21.0–45.0) in the SEQ group (P5 .48). The 2-year CIR was 57%,
95%CI (41–72) in the MAC group and 50%, 95%CI (37–63) in the SEQ
group (P5 .99). The 2-year NRM was 15% (95%CI (4.0–26.0)) in the
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MAC group and 17% 95%CI (7.0–27.0) in the SEQ group (P5 .44). Var-
iables associated with post-transplant outcomes in univariate analysis
are provided in Table 2.
The patients who received a FLAMSA regimen and those who
received the clofarabine/cytarabine regimen had similar OS (HR for
FLAMSA: 1, 95%CI (0.53–1.88); P51.0), CIR (HR for FLAMSA: 1.01,
95%CI (0.51–2.0); P5 .98) and NRM (HR for FLAMSA: 0.99, 95%CI
(0.31–3.17); P5 .98). There was also no difference in the MAC group
between TBI or busulfan based regimens with respect to OS (HR for
TBI: 0.85, 95%CI (0.40–1.8); P5 .67), CIR (HR for TBI: 1.1, 95%CI
(0.51–2.37); P5 .81), NRM (HR for TBI: 0.27, 95%CI (0.03–2.32);
P5 .23) and cGVHD (HR for TBI: 1.89, 95%CI (0.76–4.75); P5 .17).
3.4 | Risk factors for post-transplant outcomes in
multivariate analysis
In multivariate analysis, sequential regimen remained associated with a
lower incidence of grade II-IV aGVHD (HR: 0.37, 95%CI (0.21–0.65);
P< .001) but not with cGVHD (all grades and extensive). Variable asso-
ciated with all grades cGVHD in multivariate analysis were CMV
donor/recipient status (HR: 0.46, 95%CI (0.43–0.49); P5 .03) and ATG
use in the conditioning regimen (HR: 0.41, 95%CI (0.20–0.87)
P5 .019). ATG use was the only variable associated with extensive
cGVHD (HR: 0.15, 95%CI (0.03–0.66); P5 .012) (Table 2).
In multivariate analysis including the conditioning regimen type,
two variables were significantly associated with OS: relapse status (HR:
1.66, 95%CI (1.03–2.66); P5 .036) and a higher blood blast percentage
at HSCT analyzed as a continuous variable, (HR: 1.01, 95%CI (1.01–
1.02); P< .001).
A worse DFS was observed in patients with (a) more than 6 months
elapsing between diagnosis and treatment (HR: 1.65, 95%CI (1.04–
2.61); P5 .035), (b) a higher blood blast percentage (HR: 1.01, 95%CI
(1.01–1.02); P5 .001) and c) a lower CD34 infused cell dose analyzed as
a continuous variable (HR: 0.93, 95%CI (0.86–1.0); P5 .049).
Relapse status at transplant (HR: 2,03, 95%CI (1.2–3.46); P5 .009),
a higher number of pretransplant chemotherapy lines (HR: 1.56, 95%CI
(1.08–2.23); P5 .017), and a higher blood blast percentage at trans-
plant (HR: 1.01, 95%CI (1.01–1.02); P5 .004) were independently
associated with higher post–transplant CIR, while there was no signifi-
cant prognostic factor for NRM in our cohort.
After excluding from the analyses the four patients, who had
received only one induction therapy before transplant and the two
patients lacking a hematopoietic recovery 50 days after induction ther-
apy, the conditioning regimen remained not statistically associated with
OS, DFS, NRM, CIR, cGVHD but is still significantly associated with
aGVHD (Supporting Information Table S1).
3.5 | Subgroup analysis
To identify a subgroup of patients who may benefit from the SEQ or
the MAC approaches, we analyzed the impact of the conditioning regi-
men according to the presence of blood blasts at transplant and to the
TABLE 1 Patient characteristics
Total MAC SEQ P value
Number of patients, n (%) 99 41 (41%) 58 (59%)
Age in years, median (range) 40 (18–50) 40 (19–50) 39 (18–49) P5 .97
Male gender, n (%) 48 (48%) 20 (49%) 28 (48%) P5 .96
ELN classification at diagnosis, n (%)
Favorable 4 (4%) 2 (5%) 2 (4%) P5 .62
Intermediate-1 30 (34%) 14 (36%) 16 (32%)
Intermediate-2 21 (24%) 9 (23%) 12 (24%)
Adverse 34 (38%) 14 (36%) 20 (40%)
Missing (n) 10 2 8
Pretransplant chemotherapy lines, median (range) 2 (1–3) 2 (1–3) 2 (1–3) P5 .49
Time from diagnosis to day of transplant
(months), median (range)
6.5 (2–121) 5 (2–18.5) 7.5 (2–121) P5 .055
Disease status at transplant, n (%)
Refractory 51 (51%) 21 (51%) 30 (52%) P5 .96
Relapsed 48 (49%) 20 (49%) 28 (48%)
First relapse 40 (83%) 16 (80%) 24 (86%)
Second relapse 8 (17%) 4 (20%) 4 (14%)
Biologic parameters at transplant
Blood blasts (%), median (range) 2 (0–93) 1 (0–85) 7 (0–93) P5 .02
Missing (n) 3 0 3
Bone Marrow blasts (%), median (range) 20 (0–96) 13 (0–86) 25 (0–96) P5 .34
Missing (n) 19 5 14
White blood cells (G/L), median (range) 2.4 (0–88) 2.7 (0.1–84) 2.2 (0–88) P5 .96
Missing (n) 1 1 0
ELN, European LeukemiaNet; HSCT, hematopoietic stem cell transplantation; MAC, myeloablative conditioning regimen transplant; SEQ, sequential
conditioning regimen transplant.
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status at transplant. There was no difference between the two condi-
tioning regimen neither for patients transplanted in absence of blood
blasts at transplant (HR for the SEQ group: 0.95, 95%IC (0.40–2.24);
P5 .91), nor for patients transplanted with 1% of blood blasts (HR
for the SEQ group: 1.42, 95%IC (0.80–2.55); P5 .22). Likewise, there
was no advantage of one or the other conditioning regimen for refrac-
tory patients (HR for the SEQ group: 1.34, 95%CI (0.66–2.72); P5 .41)
or for relapsed patients (HR for the SEQ group: 1.11, 95%CI (0.59–
2.1); P5 .74).
4 | DISCUSSION
As promising results have been reported with sequential transplants in
refractory or relapsed AML, this approach is usually preferred to MAC
transplants traditionally associated with high NRM in this population.
However, the optimal choice of conditioning regimen is still an open
question. The improvement of supportive care in HSCT over the last dec-
ades, translating into reduced NRM in MAC transplants, leads to reassess
the place of MAC versus sequential approach in refractory or relapsing
AML patients. The main objective of this study was to compare the out-
come of relapsed/refractory AML patients transplanted after a conven-
tional MAC regimen or a sequential approach. As MAC transplant is not
usually proposed to patients over 50 years, we have limited the inclusions
to younger patients who were transplanted since 2006, which corre-
sponds to the onset of the sequential transplant approach in France. To
our knowledge, this is the first study designed to compare these two
approaches of transplant. In a recent report evaluating long-term out-
comes of patients transplanted for refractory AML, no difference in sur-
vival was observed after a FLAMSA-RIC, and a MAC regimen.32
TABLE 2 Risk factors for GVHD, OS, DFS, CIR
Univariate analysisa Multivariate analysis
HR 95% CI P value HR 95% CI P value
aGVHD (grade II–IV)
Conditioning type: Sequential 0.37 0.21–0.65 <.001 0.37 0.21–0.65 <.001
Female donor to male recipient 1.63 0.94–2.82 .081
Use of ATG 0.40 0.23–0.71 .0017
cGVHD (all grades)
Conditioning type: Sequential 0.50 0.25–0.99 .049
Use of ATG 0.48 0.24–0.98 .043 0.41 0.20–0.87 .019
CD341 cell dose§ 1.06 0.99–1.13 .086
All CMV status vs CMV recipient -/donor - 0.46 0.23–0.92 .029 0.46 0.43–0.49 .029
cGVHD (extensive)
Conditioning type: Sequential 0.30 0.09–0.96 .043
Female donor to male recipient 2.70 0.89–8.06 .08
Use of ATG 0.15 0.03–0.66 .012 0.15 0.03–0.66 .012
CD341 cell dose§ 1.09 0.99–1.20 .096
OS
Time diagnosis/transplant>6 months 1.64 1.03–2.61 .037
Status at transplant: Relapse 1.8 1.13–2.9 .013 1.66 1.03–2.66 .036
Blood blasts at transplant§ 1.01 1.01–1.02 <.001 1.01 1.01–1.02 <.001
Bone marrow blasts at transplant§ 1.01 1.01–1.02 .047
White blood cells count at transplant§ 1.16 0.97–1.39 .09
CD341 cell dose§ 0.91 0.85–0.99 .02
DFS
Time diagnosis/transplant>6 months 1.51 0.96–2.38 .076 1.65 1.04–2.61 .035
Status at transplant: Relapse 1.78 1.13–2.81 .013
Blood blasts at transplant§ 1.01 1.01–1.02 <.001 1.01 1.01–1.02 .001
White blood cells count at transplant§ 1.03 1.01–1.04 .003
CD341 cell dose§ 0.92 0.85–0.99 .026 0.93 0.86–1 .049
CIR
Number of pre transplant chemotherapy lines§ 1.64 1.16–2.32 .005 1.56 1.08–2.23 .017
Status at transplant: Relapse 1.89 1.13–3.17 .016 2.03 1.2–3.46 .009
Blood blasts at transplant§ 1.01 1.01–1.02 .005 1.01 1.01–1.02 .004
Bone marrow blasts at transplant§ 1.01 1.01–1.02 .01
aGVHD, acute graft versus host disease; cGVHD, chronic graft versus host disease; CMV, cytomegalovirus; CI, confidence interval; CIR, cumulative
incidence of relapse; DFS, disease free survival; HR, hazard ratio; OS, overall survival.
aThe univariate analysis had included the following variables: ELN classification, number of pretransplant chemotherapy lines §, age at transplant §, time
between diagnosis and transplant (shorter or longer than 6 months), status at transplant (refractory or relapse), percentage of blood blasts at transplant
§, percentage of bone marrow blasts at transplant §, white blood cell count at transplant §, conditioning regimen type at transplant, hematopoietic stem
cell source, donor type, donor gender, ATG, CMV status and CD341 cell dose §.
§Variables analyzed as continuous variables.
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Our results showing a 2-year OS of about 40% compared favor-
ably with previous series of MAC and sequential HSCT in relapsing or
refractory AML.9,10,12,15,19–21,23,32–35 Patients from two groups did not
differ in regards to their major characteristics, especially the distribution
between refractory and relapsed leukemia. Types of donor and stem
cell sources were not significantly different between the 2 groups, but
most patients in the SEQ group received ATG in their conditioning regi-
men, unlike patients of the MAC group (84% versus 10%, P< .001).
We observed very close OS, DFS, relapse and NRM after a SEQ or a
MAC transplant, and we failed to identify a subset of patients benefit-
ing from one of these approaches rather than the other. The 2-year
NRM of 17% we observed in the MAC group, was lower than reported
in the historical series,12,13,17 reflecting the progress in supportive care
during the last decades.25,27 We confirm here that refractory status is
associated with a better OS than relapse status, as previously reported
in the setting of sequential transplant.19 Furthermore, Holtick et al
recently showed that PIF and high-risk AML transplanted in first CR
display identical OS and DFS after FLAMSA regimen, suggesting that
patients in PIF seem to really benefit from early stem cell transplanta-
tion.22 The main difference between the 2 approaches was a lower
incidence of grade II-IV aGVHD observed in the SEQ group. This differ-
ence remained significant in multivariate analysis including ATG, but
did not translate into lower cGVHD. Interestingly, RIC regimen seems
to be less toxic to gonads. In our experience, two spontaneous preg-
nancies were observed a few years after SEQ transplant in two young
females (N. Dhedin et al., unpublished data).
One limit of this retrospective study is to ignore the reason why
physicians choose a SEQ approach or a MAC conditioning regimen.
Moreover, each group of treatment featured different types of condi-
tioning regimen: TBI or busulfan based regimen in the MAC group and
clofarabine plus aracytine versus FLAMSA regimens in the SEQ group.
Finally, the main difference was a more frequent use of ATG in the
SEQ group, which had a major impact on chronic GVHD occurrence, as
previously reported.36–38
In high-risk AML, relapse after transplant remains the major cause
of death, leading to the recommendation of prophylactic DLI in the
sequential approach. In several series of SEQ transplants, the addition
of prophylactic DLI was associated with prolonged OS achieving 67%
at 7 years in a large report from the German group.19,39–41 In our retro-
spective study, only 8.6% of patients transplanted after a SEQ
approach actually received prophylactic DLI. That is lower than previ-
ously reported in the experience of the German group.18–20 However,
in most studies of SEQ transplant, prophylactic DLI did not exceed
25%,18–20,23,34 due to early transplant mortality, early relapse or GVHD
occurrence, actually showing the poor feasibility of this strategy.
Another way of reducing post-transplant relapse in SEQ approach
could be to reinforce the pretransplant cytoreduction by using news
drugs. A second generation of purine analog, clofarabine, which also
shown to be relevant in first line or in relapsed of AML,42–44 was thus
evaluated in the setting of sequential transplant.21,35 In our series there
is no superiority of a clofarabine/cytarabine-RIC compared with a more
classic FLAMSA-RIC regimen. These data are consistent with the
results of the prospective SETRIC trial reporting a 2-year OS of 38%
after a clofarabine/cytarabine-RIC in refractory AML patients.21 Finally,
new strategies of maintenance therapies are being developed, alone or
in combination with prophylactic DLI to avoid post-transplant relapse.
The hypomethylating agent azacitidine or the tyrosine kinase inhibitor
sorafenib for FLT3-ITD patients have shown tolerability and feasibility
as maintenance therapies after transplant and seem to improve OS and
FIGURE 1 Post transplant outcomes according to the treatment
group Black curve: myeloablative transplant, gray curve: sequential
approach. (A) Overall Survival (B) Cumulative incidence of relapse
(C) Non relapse mortality
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DFS rates.45,46 Such therapies, including also new tyrosine kinase inhib-
itors that can target a broader spectrum of patients, have to be eval-
uated in these patients, especially in those at a very high risk of
relapse, such as patients with persisting blood blasts.
In conclusion, our study shows that, for young patients with refrac-
tory or relapsed AML, OS, DFS, NRM and CIR appear to be similar after
sequential and myeloablative transplants. Lower acute GVHD incidence
in the sequential group did not lead to lower cGVHD. Post-transplant
relapse remains a major issue and maintenance therapy after transplant
is a promising possibility, which has to be prospectively evaluated.
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